Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: COVID-19, Sars-CoV2

In brief

The purpose of this study assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms up to 14 days after the onset of initial symptoms.

Key facts

Study ID
NCT04421404
Run by
Priscilla Hsue, MD
People needed
34
Starts
2020-06-09
Expected to finish
2021-04-30
Last updated by the study team
2022-10-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.